Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 3/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29736294 | 0.87 | HDAC1 (0.52) | GPR119HSD11B1HDAC1JAK1CHRM2 | |
| SCHEMBL2305956 | 0.87 | HDAC1 (0.52) | GPR119HSD11B1HDAC1JAK1CHRM2 | |
| SCHEMBL15034395 | 0.85 | HSD11B1 (0.45) | GPR119HSD11B1HDAC1JAK1CHRM2 | |
| SCHEMBL25738114 | 0.84 | GPR119 (0.48) | GPR119HSD11B1HDAC1JAK1CHRM2 | |
| SCHEMBL20469236 | 0.83 | GPR119 (0.59) | GPR119HSD11B1HDAC1JAK1CHRM2 | |
| SCHEMBL25738115 | 0.83 | HDAC1 (0.48) | GPR119HSD11B1HDAC1JAK1CHRM2 | |
| SCHEMBL2302595 | 0.83 | MAPT (0.54) | GPR119HSD11B1HDAC1JAK1MAPT | |
| SCHEMBL31106300 | 0.83 | MAPT (0.54) | GPR119HSD11B1HDAC1JAK1MAPT | |
| SCHEMBL25188860 | 0.82 | HDAC1 (0.48) | GPR119HSD11B1HDAC1JAK1CHRM2 | |
| SCHEMBL31173950 | 0.82 | HDAC1 (0.48) | GPR119HSD11B1HDAC1JAK1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130150342-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150342-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | CDK4, CDK6, CCNT1 | GPR119 2573/4885HSD11B1 2556/4885HDAC1 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.